Alkem Laboratories Limited has informed the Exchange regarding a press release dated October 10, 2024, titled "ALKEM signs a licensing agreement with M/s. Sonnet BioTherapeutics Holdings, Inc. to develop and commercialize SON-080 for Diabetic Peripheral Neuropathy in India.".